These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 14634434)

  • 21. Chemotherapy and prostate cancer.
    Dacker R
    Radiol Technol; 1997; 68(3):194-5. PubMed ID: 9008013
    [No Abstract]   [Full Text] [Related]  

  • 22. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
    Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
    Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The opportunity cost of androgen suppression in locally advanced prostate cancer.
    Gray PJ; Efstathiou JA; Shipley WU
    Asian J Androl; 2013 May; 15(3):356-7. PubMed ID: 23435474
    [No Abstract]   [Full Text] [Related]  

  • 24. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
    Polascik TJ; Given RW; Metzger C; Julian SR; Vestal JC; Karlin GS; Barkley CS; Bilhartz DL; McWhorter LT; Lacerna LV
    Urology; 2005 Nov; 66(5):1054-9. PubMed ID: 16286123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Harms versus benefits with duration of androgen suppression.
    Nguyen PL
    Lancet Oncol; 2012 Dec; 13(12):1182-3. PubMed ID: 23151430
    [No Abstract]   [Full Text] [Related]  

  • 26. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy.
    Yaturu S; DjeDjos S; Alferos G; Deprisco C
    Prostate Cancer Prostatic Dis; 2006; 9(1):35-8. PubMed ID: 16276350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer.
    Mohamad NV; Soelaiman IN; Chin KY
    Endocr Metab Immune Disord Drug Targets; 2017 Nov; 17(4):276-284. PubMed ID: 28925899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trials test bisphosphonates in hormone-sensitive prostate cancer.
    Bankhead C
    J Natl Cancer Inst; 2003 Sep; 95(17):1273-4. PubMed ID: 12953081
    [No Abstract]   [Full Text] [Related]  

  • 31. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer.
    Malik R; Jani AB; Liauw SL
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1022-8. PubMed ID: 20510547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
    Takahashi S
    Clin Calcium; 2011 Mar; 21(3):447-53. PubMed ID: 21358067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Total androgen blockade].
    Namiki M; Mizokami A
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
    [No Abstract]   [Full Text] [Related]  

  • 34. Titration of dosage for the protective effect of zoledronic acid on bone loss in patients submitted to androgen deprivation therapy due to prostate cancer: a prospective open-label study.
    Rodrigues P; Meler A; Hering F
    Urol Int; 2010; 85(2):180-5. PubMed ID: 20628233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controversies surrounding hormonal deprivation.
    Denis LJ
    Acta Urol Belg; 1996 May; 64(2):81-4. PubMed ID: 8701819
    [No Abstract]   [Full Text] [Related]  

  • 36. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR
    Drugs Aging; 2003; 20(3):175-83. PubMed ID: 12578398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonsteroidal anti-androgens: role in treating advanced prostate cancer.
    Newton M; Kosier JH
    Urol Nurs; 1998 Mar; 18(1):56-7, 83. PubMed ID: 9582897
    [No Abstract]   [Full Text] [Related]  

  • 38. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
    Green JR
    Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of bisphosphonates in prostate cancer.
    Saad F; Schulman CC
    Eur Urol; 2004 Jan; 45(1):26-34. PubMed ID: 14667511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.